Gast ::
| Hauptseite > Publikationsdatenbank > Structural analysis of the pyroglutamate modified isoform of the Alzheimer's disease related beta-amyloid using NMR spectroscopy > print |
| Hauptseite > Publikationsdatenbank > Structural analysis of the pyroglutamate modified isoform of the Alzheimer's disease related beta-amyloid using NMR spectroscopy > print |
| 001 | 23150 | ||
| 005 | 20200402210322.0 | ||
| 024 | 7 | _ | |2 pmid |a pmid:23001756 |
| 024 | 7 | _ | |2 DOI |a 10.1002/psc.2456 |
| 024 | 7 | _ | |2 WOS |a WOS:000310029900006 |
| 037 | _ | _ | |a PreJuSER-23150 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |0 P:(DE-Juel1)VDB106075 |a Sun, N. |b 0 |u FZJ |
| 245 | _ | _ | |a Structural analysis of the pyroglutamate modified isoform of the Alzheimer's disease related beta-amyloid using NMR spectroscopy |
| 260 | _ | _ | |a New York, NY [u.a.] |b Wiley |c 2012 |
| 300 | _ | _ | |a 691 - 695 |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 440 | _ | 0 | |0 18981 |a Journal of Peptide Science |v 18 |x 1075-2617 |y 11 |
| 500 | _ | _ | |a Record converted from VDB: 12.11.2012 |
| 520 | _ | _ | |a The aggregation of the Aβ plays a fundamental role in the pathology of AD. Recently, N-terminally modified Aβ species, pE-Aβ, have been described as major constituents of Aβ deposits in the brains of AD patients. pE-Aβ has an increased aggregation propensity and shows increased toxicity compared with Aβ1-40 and Aβ1-42. In the present work, high-resolution NMR spectroscopy was performed to study pE-Aβ3-40 in aqueous TFE-containing solution. Two-dimensional TOCSY and NOESY experiments were performed. On the basis of NOE and chemical shift data, pE-Aβ3-40 was shown to contain two helical regions formed by residues 14-22 and 30-36. This is similar as previously described for Aβ1-40. However, the secondary chemical shift data indicate decreased helical propensity in pE-Aβ3-40 when compared with Aβ1-40 under exactly the same conditions. This is in agreement with the observation that pE-Aβ3-40 shows a drastically increased tendency to form β-sheet-rich structures under more physiologic conditions. Structural studies of pE-Aβ are crucial for better understanding the structural basis of amyloid fibril formation in the brain during development of AD, especially because an increasing number of reports indicate a decisive role of pE-Aβ for the pathogenesis of AD. Copyright © 2012 European Peptide Society and John Wiley & Sons, Ltd. |
| 536 | _ | _ | |0 G:(DE-Juel1)FUEK409 |2 G:(DE-HGF) |a Funktion und Dysfunktion des Nervensystems |c P33 |x 0 |
| 536 | _ | _ | |0 G:(DE-Juel1)FUEK505 |a BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |c P45 |x 1 |
| 588 | _ | _ | |a Dataset connected to Pubmed |
| 700 | 1 | _ | |0 P:(DE-Juel1)VDB57647 |a Hartmann, R. |b 1 |u FZJ |
| 700 | 1 | _ | |0 P:(DE-Juel1)VDB94799 |a Lecher, J. |b 2 |u FZJ |
| 700 | 1 | _ | |0 P:(DE-Juel1)VDB21601 |a Stoldt, M. |b 3 |u FZJ |
| 700 | 1 | _ | |0 P:(DE-Juel1)VDB101069 |a Funke, S.A. |b 4 |u FZJ |
| 700 | 1 | _ | |0 P:(DE-Juel1)VDB109415 |a Gremer, L. |b 5 |u FZJ |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Ludwig, H.-H. |b 6 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Demuth, H.U. |b 7 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Kleinschmidt, H. |b 8 |
| 700 | 1 | _ | |0 P:(DE-Juel1)132029 |a Willbold, D. |b 9 |u FZJ |
| 773 | _ | _ | |0 PERI:(DE-600)1491819-5 |a 10.1002/psc.2456 |g Vol. 18, p. 691 - 695 |p 691 - 695 |q 18<691 - 695 |t Journal of peptide science |v 18 |x 1075-2617 |y 2012 |
| 856 | 7 | _ | |u http://dx.doi.org/10.1002/psc.2456 |
| 909 | C | O | |o oai:juser.fz-juelich.de:23150 |p VDB |
| 913 | 1 | _ | |0 G:(DE-Juel1)FUEK409 |1 G:(DE-HGF)POF2-330 |2 G:(DE-HGF)POF2-300 |b Gesundheit |k P33 |l Funktion und Dysfunktion des Nervensystems |v Funktion und Dysfunktion des Nervensystems |x 0 |
| 913 | 1 | _ | |0 G:(DE-Juel1)FUEK505 |1 G:(DE-HGF)POF2-450 |2 G:(DE-HGF)POF2-400 |b Schlüsseltechnologien |k P45 |l Biologische Informationsverarbeitung |v BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |x 1 |
| 913 | 2 | _ | |0 G:(DE-HGF)POF3-553 |1 G:(DE-HGF)POF3-550 |2 G:(DE-HGF)POF3-500 |a DE-HGF |b Key Technologies |l BioSoft Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |v Physical Basis of Diseases |x 0 |
| 914 | 1 | _ | |y 2012 |
| 915 | _ | _ | |a JCR/ISI refereed |0 StatID:(DE-HGF)0010 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |g ICS |k ICS-6 |l Strukturbiochemie |x 0 |
| 970 | _ | _ | |a VDB:(DE-Juel1)140115 |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a ConvertedRecord |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 980 | _ | _ | |a UNRESTRICTED |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|